Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening
暂无分享,去创建一个
[1] C. Mian,et al. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience , 2018, World Journal of Surgery.
[2] Jin Hwa Kim,et al. Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis , 2017, World Journal of Surgery.
[3] S. Roman,et al. Surgical management of medullary thyroid carcinoma , 2017, Updates in Surgery.
[4] David F Schneider,et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years , 2017, Surgery.
[5] H. Dralle,et al. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. , 2016, European journal of endocrinology.
[6] Jeong Hyun Lee,et al. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma , 2016, Journal of surgical oncology.
[7] 정종주,et al. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years , 2016 .
[8] Douglas B. Evans,et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.
[9] T. Samulski,et al. The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: an institutional experience. , 2014, Pathology, research and practice.
[10] S. Roman,et al. Medullary thyroid microcarcinoma , 2012, Cancer.
[11] M. Schlumberger,et al. Medullary thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[12] S. Roman,et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. , 2008, The Journal of clinical endocrinology and metabolism.
[13] C. Bieglmayer,et al. Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. , 2007, Surgery.
[14] A. Pinchera,et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. , 2007, The Journal of clinical endocrinology and metabolism.
[15] E. Kebebew,et al. Extent of disease and practice patterns for medullary thyroid cancer. , 2005, Journal of the American College of Surgeons.
[16] F. Sebag,et al. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] Erik G. Cohen,et al. Medullary thyroid carcinoma , 2004, Acta oto-laryngologica.
[18] A. Pinchera,et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. , 2004, The Journal of clinical endocrinology and metabolism.
[19] J. Hahm,et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. , 2001, Thyroid : official journal of the American Thyroid Association.
[20] Q. Duh,et al. Medullary thyroid carcinoma , 2000, Cancer.
[21] O. Haas,et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. , 1998, The American journal of surgical pathology.
[22] M. Schlumberger,et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .
[23] M. Schlumberger,et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. , 1998, Clinical endocrinology.